May Health is focused on evaluating its innovative Ovarian Rebalancing™ technology, designed to help women with PCOS who face infertility. This is a one-time procedure that aims to restore ovulation.
PARIS, March 10, 2025 — May Health, a clinical-stage medical device company with locations in Paris and California, has appointed Colby Holtshouse as its new President and CEO. Colby comes to the role with significant experience in women’s health, having held key positions at companies like Organon, Alydia Health, and Pelvalon.
“We’re thrilled to have Colby on board, especially as we work toward the conclusion of our REBALANCE study,” said Dr. Robert Auerbach, Chairman of May Health. “Her expertise in bringing innovative technologies to market makes her a perfect choice for leading our team to help millions of women dealing with PCOS-related infertility.”
PCOS is a hormone disorder that affects about 10% of women of reproductive age and is a common cause of infertility. Symptoms can include irregular periods, acne, weight gain, and excess hair growth. Unfortunately, the condition can also raise the risk of long-term health issues like diabetes and heart disease.
May Health’s Ovarian Rebalancing is a unique treatment aimed at restoring normal ovulation in women who do not respond to traditional medications. The procedure uses ultrasound technology and radiofrequency energy to target ovarian tissue that produces excess male hormones. It’s designed to be minimally invasive and allows women to recover quickly, often resuming normal activities the same day.
“I’m excited to join May Health at such a pivotal moment. The results from our earlier studies are promising, and we are hopeful that the REBALANCE trial will help us secure FDA approval for our treatment,” Colby said. “I look forward to collaborating with the May Health team to bring this innovative solution to women who need it.”
About May Health
Founded in 2012 and based in Paris and California, May Health is working on cutting-edge treatments for women suffering from PCOS. Their Ovarian Rebalancing technology is currently in clinical trials to support FDA approval. The team consists of experienced professionals in the medtech and women’s health sectors, dedicated to creating effective solutions for patients. The company recently raised $25 million to advance its goals.
For more information, you can visit May Health’s website.
Check out this related article: Crozer Health System in Pennsylvania Secures Future: No Shutdown After All, Officials Confirm
Source linkOGN stock news, OGN news, OGN stock, OGN latest news
